Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 (IFRS)

November 5, 2026

Listed Company Name:	Santen Pharmaceutical Co., Ltd.
Exchanges Listed:	Tokyo (Prime Market)
Stock Code:	4536
URL:	https://www.santen.com/en
Representative:	Takeshi Ito, President and CEO
Contact:	Guillaume Sakuma, Global Head of Investor Relations (+81-6-7664-8621)
Filing of Securities Report (Scheduled):	November 9, 2026
Start of Distribution of Dividends (Scheduled):	November 30, 2026
Preparation of Supplementary Material of the Financial Results:	Yes
Holding of Presentation of Financial Results:	Yes (for securities analysts and institutional investors)

(JPY millions)

1. Consolidated Performance for the Six Months Ended September 30, 2026

(1) Operating Results

	Six months ended September 30, 2025	Six months ended September 30, 2026	Change
Revenue	137,879	143,289	+3.9%
Core operating profit	22,314	23,932	+7.3%
Operating profit	17,915	19,411	+8.4%
Net profit for the period	13,854	15,478	+11.7%
Net profit for the period attributable to owners of the company	13,940	15,447	+10.8%
Total comprehensive income for the period	22,089	13,992	(36.7%)
Basic earnings per share (yen)	41.76	48.05	
Diluted earnings per share (yen)	41.70	47.97	

(2) Financial Position

	March 31, 2026	September 30, 2026
Total assets	423,033	418,450
Total equity	296,017	303,331
Equity attributable to owners of the company	296,989	304,284
Ratio of equity attributable to owners of the company to total assets (%)	70.2	72.7
Equity per share attributable to owners of the company (yen)	923.75	945.82

2. Dividends

	Year to March 2026	Year to March 2027	(Forecasts) Year to March 2027
First quarter dividends per share (yen)	—	—	—
Second quarter dividends per share (yen)	19.00	21.00	—
Third quarter dividends per share (yen)	—	—	—
Year-end dividends per share (yen)	19.00	—	21.00
Annual dividends per share (yen)	38.00	—	42.00

(Note):

Revisions to the forecasts of dividends from the latest announcement: No

3. Consolidated Forecasts of Results for the Fiscal Year Ending March 31, 2027

	Year to March 2027	Change
Revenue	311,000	+6.6%
Core operating profit	59,000	+7.0%
Operating profit	49,500	+3.6%
Net profit for the year	39,500	+5.2%
Net profit for the year attributable to owners of the company	40,000	+7.0%
Basic earnings per share (yen)	127.56	+11.9%

(Note):

Revisions to the forecasts of consolidated results from the latest announcement: No

1. Please refer to "1. Summary of Consolidated Results and Others (1) Summary of Consolidated Results for the Period" on page 3 of the attached material for details of the reconciliation from IFRS basis figures to core-based figures.
2. At a meeting of the Board of Directors on November 5, 2026, the Board resolved to repurchase treasury shares. The impact of the share repurchases has been factored into the basic earnings per share forecasts for the year ending March 31, 2027. Please refer to “2. Condensed Interim Consolidated Financial Statements and Major Notes (5) Notes to Condensed Interim Consolidated Financial Statements” on page 14 for details of the repurchase of treasury shares.

*Notes

(1) Significant changes in scope of consolidation during the period: No

(2) Changes in accounting policies and accounting estimates

(i) Changes in accounting policies required by IFRS : No
(ii) Changes in accounting policies other than (i) : No
(iii) Changes in accounting estimates : No

(3) Number of ordinary shares issued

(i) Number of shares outstanding at the end of period (including treasury shares)

September 30, 2026	322,314,154 shares
March 31, 2026	322,281,654 shares

(ii) Number of treasury shares at the end of period

September 30, 2026	535,616 shares
March 31, 2026	602,813 shares

(iii) Weighted average number of outstanding shares

The second quarter ended September 30, 2026	321,418,921 shares
The second quarter ended September 30, 2025	333,666,908 shares

(Note):
The number of treasury shares at the end of the period includes shares (28,410 shares for the fiscal year ended March 31, 2026 and 30,025 shares as of September 30, 2026 of the fiscal year ending March 31, 2027) owned in trust for the stock compensation system. Such shares are included in the treasury shares which are excluded from the calculation of the weighted average number of shares outstanding during the period.

*This financial summary is not subject to review by a certified public accountant or auditing firm.

*Explanations and other special notes concerning the appropriate use of business performance forecasts

(Notes on forward-looking statements)
The earnings forecasts and other forward-looking statements contained in this report are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual results may differ from these forecasts due to various factors.

(Method of obtaining supplementary explanatory materials for financial results and results presentation contents)
The Santen Group plans to hold a briefing on the results for securities analysts and institutional investors on Thursday, November 5, 2026. The materials used in this briefing will be posted on our website.

Accompanying Materials – Contents

1. Summary of Consolidated Results and Others…….. 2
(1) Summary of Consolidated Results for the Period..... 2
(2) Summary of Financial Position for the Period..... 5
(3) Information about Forecasts of Consolidated Financial Results and Other Forward-Looking Statements…… 5
2. Condensed Interim Consolidated Financial Statements and Major Notes..... 6
(1) Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income…… 6
(2) Condensed Interim Consolidated Statements of Financial Position..... 7
(3) Condensed Interim Consolidated Statements of Changes in Equity..... 9
(4) Condensed Interim Consolidated Statements of Cash Flows..... 11
(5) Notes to Condensed Interim Consolidated Financial Statements 12
(Going Concern Assumption)..... 12
(Segment Information and Others)..... 12
(Statement of Significant Changes in Shareholders' Equity)..... 12
(Disposal groups classified as held for sale)…… 13
(Significant Subsequent Events)..... 14
3. Consolidated Reference..... 15
(1) Revenue of Major Products..... 15
(2) Research & Development..... 16
(3) Capital Expenditures, Depreciation and Amortization, Amortization of Intangible Assets Associated with Products, and Research and Development Expenses..... 18
(4) FOREX..... 18

1. Summary of Consolidated Results and Others

(1) Summary of Consolidated Results for the Period

(I) Consolidated Results

(JPY billions)

	Six months ended September 30, 2025	Six months ended September 30, 2026	Year-on-year change
Revenue	137.9	143.3	3.9%
Core operating profit[*1]	22.3	23.9	7.3%
Operating profit	17.9	19.4	8.4%
Net profit for the period	13.9	15.5	11.7%
Net profit for the period attributable to owners of the company	13.9	15.4	10.8%
EBITDA[*2]	27.1	28.4	5.0%

[Revenue]

Revenue in the six months ended September 30, 2026 increased by 3.9% year-on-year to ¥143.3 billion. This was mainly due to the focus on expanding sales of new and mainstay products despite the impact of NHI price revisions.

◇ Japan

The Company focused on expanding sales of new products, including *Ryjusea* and *EYLEA 8mg kit for IVT inj. 114.3mg/mL* which were launched in 2025, *Upneeq*, which was launched in May 2026, and *Rhopressa* which was launched in August 2026, as well as mainstay products such as *Diquas LX*, shipments of which resumed in December 2025. Revenue in the six months ended September 30, 2026 decreased by 12.4% year-on-year to ¥61.2 billion. This was mainly due to the impact of market expansion re-pricing and the entry of generic drugs for a mainstay product. Within total Japan revenue, revenue from OTC increased by 0.7% year-on-year to ¥6.1 billion.

◇ China

On a JPY basis, revenue in the six months ended September 30, 2026 increased by 13.6% year-on-year (-1.2% excluding FX impact) to ¥16.6 billion. This was mainly due to growth in the mainstay product *Cravit* and the contribution of an exclusive promotion and distribution agreement for five glaucoma eye drops including *Alphagan/AlphaganP* in the Chinese Mainland from April 2026.

◇ Asia (excluding China)

On a JPY basis, revenue in the six months ended September 30, 2026 increased by 33.6% year-on-year (+26.6% excluding FX impact) to ¥19.9 billion. This was mainly due to the steady growth of glaucoma and dry eye products and the contribution of an exclusive promotion and distribution agreement for VEGF inhibitors, *Beovu* and *Lucentis*, in South Korea from October 2025.

◇ EMEA[*3]

On a JPY basis, revenue in the six months ended September 30, 2026 increased by 17.8% year-on-year (+7.1% excluding FX impact) to ¥44.5 billion. This was mainly due to the focus on expansion of mainstay glaucoma and dry eye products and *Ryjunea*, which was launched in 2025.

[Core operating profit]

Gross profit in the six months ended September 30, 2026 increased by 7.1% year-on-year to ¥82.7 billion.
SG&A expenses in the six months ended September 30, 2026 increased by 9.7% year-on-year (+3.0% excluding FX impact) to ¥46.6 billion.
R&D expenses in the six months ended September 30, 2026 decreased by 1.9% year-on-year (-7.5% excluding FX impact) to ¥12.1 billion.

As a result, operating profit on a core basis in the six months ended September 30, 2026 increased by 7.3% year-on-year (+0.4% excluding FX impact) to ¥23.9 billion.

[Operating profit]

As non-core expenses adjusted from the core basis, expenses related to streamlining of ¥0.2 billion each were recorded in SG&A and R&D expenses respectively in the six months ended September 30, 2026.

Amortization on intangible assets associated with products in the six months ended September 30, 2026 decreased by 7.2% year-on-year (-10.2% excluding FX impact) to ¥4.1 billion. This was mainly due to the amortization on intangible assets associated with products acquired from Merck & Co., Inc. (U.S.) in 2014, *PRESERFLO MicroShunt* which was launched in Europe in 2019, *Rhopressa*/*Rocklatan* which Santen began selling in Europe in 2023, Asia in 2024 and Japan in 2026, and *Upneeq* which was launched in Japan in 2026.

Other income amounted to ¥0.1 billion.
Other expenses amounted to ¥0.1 billion.

As a result, operating profit on an IFRS basis in the six months ended September 30, 2026 increased by 8.4% year-on-year (+0.7% excluding FX impact) to ¥19.4 billion.

[Net profit for the period]

Finance income amounted to ¥1.5 billion.
Finance expenses amounted to ¥1.1 billion.
Income tax expenses amounted to ¥ 4.4 billion, up ¥0.6 billion year-on-year.

As a result, net profit for the period ended September 30, 2026 increased by 11.7% year-on-year to ¥15.5 billion.

[Net profit for the period attributable to owners of the company]

Net profit for the period attributable to owners of the company in the six months ended September 30, 2026 increased by 10.8% year-on-year to ¥15.4 billion. The ratio to revenue was 10.8%.

*1 With the adoption of IFRS in the fiscal year ended March 31, 2015, the Santen Group discloses financial information on a core basis, which is calculated by excluding certain income and expense items from the IFRS basis, as an indicator of ordinary performance. The core basis is calculated by deducting the following income and expense items (non-core income and non-core expense) from IFRS results.

- Amortization on intangible assets associated with products
- Other income
- Other expenses
- Expenses related to acquisitions of companies and streamlining measures

*2 EBITDA is calculated as follows: EBITDA = (Operating profit) - (Other income) + (Other expenses) + (Depreciation and amortization)

*3 Refers to Europe, Middle East and Africa.

(II) Research & Development Activities

<Glaucoma and ocular hypertension area>

STN1011702 (generic name: omidenepag isopropyl) is an EP2 receptor agonist. Phase 3 trial was completed in China in September 2026 and met its primary endpoint.

STN1013001 (DE-130A, generic name: latanoprost) is an ophthalmic emulsion of a prostaglandin $F_{2\alpha}$ derivative. The Company filed for marketing approval in Asia in November 2024. The Company launched the product in European countries including Spain in August 2024.

STN1013900 (AR-13324, generic name: netarsudil mesylate) is a ROCK/NET inhibitor. The Company launched the product in Japan in August 2026. Marketing approval has been received in Europe, and the Company has launched the product in Sweden and other countries from February 2023 onward. The Company has successively received marketing approval in Asian countries and launched in South Korea in November 2024.

STN1014003 (generic name: netarsudil mesylate / latanoprost) is a fixed dose combination drug of a ROCK/NET inhibitor and a prostaglandin $F_{2\alpha}$ derivative. It met its primary endpoint in the pivotal phase of the Phase 3 trial being conducted in Japan since February 2025.

<Keratoconjunctival disease area including dry eye>

STN1008903 (DE-089C, generic name: diquafosol sodium) is for the treatment of dry eye. The Company filed for marketing approval in Asia in May 2026.

STN1014100 (generic name: olodaterol hydrochloride) is for the treatment of dry eye. Phase 2b trial was completed in Japan in August 2026 and met its primary endpoint.

STN1014101 (generic name: olodaterol hydrochloride) is for the treatment of allergic conjunctivitis. Phase 1/2a trial was started in Japan in March 2026.

STN1011402 (generic name: epinastine hydrochloride) is an eyelid cream for the treatment of allergic conjunctivitis. The Company launched the product in Japan in May 2024. Phase 3 trial was started in China in January 2026.

STN1011403 (generic name: epinastine hydrochloride) is a high dose formulation to instill twice a day for the treatment of allergic conjunctivitis. The Company filed for marketing approval in China in March 2025.

STN1014200 (CBT-001, generic name: nintedanib) is for the treatment of pterygium. Phase 2b trial has been under way in Japan since November 2025.

<Refractive disorder>

STN1012700 (DE-127, generic name: atropine sulfate) is for the treatment of myopia in children. The Company launched the product in Japan in April 2025. The Company filed for marketing approval in China in September 2026. In Asia, the Company received marketing approval in the Philippines in May 2026.

<Retinal diseases area>

STN1014300 (RC28-E, generic name: eflimrufusp alfa) is for the treatment of diabetic macular edema. RemeGen Co., Ltd. (China), the licensor, withdrew the filing for marketing approval in China in June 2026 and plans additional trials to fulfill final approval requirements.

STN1014301 (RC28-E, generic name: eflimrufusp alfa) is for the treatment of wet age-related macular degeneration. RemeGen Co., Ltd. (China), the licensor, completed a Phase 3 trial in China in April 2026, having met its primary endpoint.

<Others>

STN1013800 (generic name: oxymetazoline hydrochloride) is for the treatment of ptosis. The Company launched the product in Japan in May 2026. Phase 3 trial has been under way in Europe since December 2024. Phase 3 trial has been under way in China since October 2024. The Company filed for marketing approval in Asia in August 2026.

* The numbering method for development codes has changed. Both existing development codes (DE-XXX) and new development codes (STNXXXXXXX) are shown. AR-13324, RC28-E and CBT-001 are the development codes of Alcon Inc. (Switzerland), RemeGen Co., Ltd. (China) and Cloudbreak Pharma Inc. (U.S.) respectively.

(2) Summary of Financial Position for the Period

(I) Assets, equity and liabilities

Total assets as of September 30, 2026 amounted to ¥418.5 billion, down ¥4.6 billion from the end of the previous fiscal year ended March 31, 2026. Despite an increase in property, plant and equipment for expanding production capacity, there were decreases in trade and other receivables, and intangible assets.

Equity amounted to ¥303.3 billion. There was an increase of ¥7.3 billion from the end of the previous fiscal year ended March 31, 2026. This was due to an increase in retained earnings.

Liabilities amounted to ¥115.1 billion, a decrease of ¥ 11.9 billion from the end of the previous fiscal year ended March 31, 2026, reflecting decreases in other current liabilities, and trade and other payables.

As a result, the ratio of equity attributable to owners of the company to total assets increased by 2.5%-points from the end of the previous fiscal year ended March 31, 2026 to 72.7%.

The Santen Group views ROE (profit ratio to equity attributable to owners of the company) as its most important management metric. The Company aims to maximize shareholder value by focusing on both maximizing cash flow and lowering the cost of capital. While the inflow of cash from operating activities is considered the basic source of cash, the Company is also implementing measures to maximize cash-generating capability by improving working capital efficiency through the management of the cash conversion cycle. As part of this effort, the Company is liquidating trade receivables to improve ROIC (return on invested capital).

(II) Cash Flows

Cash flows from operating activities amounted to an inflow of ¥19.7 billion (inflow of ¥13.6 billion in the six months ended September 30, 2025). This was mainly due to the net profit for the period of ¥15.5 billion, ¥8.9 billion in depreciation and amortization, a decrease of ¥8.3 billion in trade and other receivables and income taxes paid of ¥4.5 billion. The Cash Conversion Ratio (CCR), which measures the conversion of profit into cash and is calculated as operating cash flow divided by EBITDA, improved from 50.1% in the same period of the previous year to 69.3%.

Cash flows from investing activities amounted to an outflow of ¥8.7 billion (outflow of ¥9.6 billion in the six months ended September 30, 2025). This was mainly due to payments for the acquisition of property, plant and equipment and intangible assets amounting to ¥4.9 billion and ¥3.9 billion respectively.

Cash flows from financing activities amounted to an outflow of ¥8.8 billion (outflow of ¥36.0 billion in the six months ended September 30, 2025). This was mainly due to cash dividends paid of ¥6.1 billion.

As a result, cash and cash equivalents at the end of September 30, 2026 increased by ¥0.8 billion from the end of the fiscal year ended March 31, 2026 to ¥81.7 billion.

(3) Information about Forecasts of Consolidated Financial Results and Other Forward-Looking Statements

The results for the period of the fiscal year under review have broadly remained in line with plan. No changes have been made to the forecasts of consolidated financial results for the year ending March 31, 2027 announced on May 12, 2026.

2. Condensed Interim Consolidated Financial Statements and Major Notes

(1) Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income

IFRS (JPY millions)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Revenue	**137,879**	**143,289**
Cost of sales	(60,679)	(60,581)
Gross profit	**77,200**	**82,707**
Selling, general and administrative expenses	(42,516)	(46,819)
Research and development expenses	(12,371)	(12,328)
Amortization on intangible assets associated with products	(4,446)	(4,127)
Other income	417	116
Other expenses	(369)	(139)
Operating profit	**17,915**	**19,411**
Finance income	884	1,529
Finance expenses	(1,164)	(1,081)
Profit before tax	**17,634**	**19,859**
Income tax expenses	(3,780)	(4,381)
Net profit for the period	**13,854**	**15,478**
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain or loss on financial assets measured at fair value through other comprehensive income	380	(84)
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	7,855	(1,262)
Share of other comprehensive income of investments accounted for using equity method	—	(140)
Other comprehensive income	**8,235**	**(1,486)**
Total comprehensive income	**22,089**	**13,992**
Net profit attributable to		
Owners of the company	13,940	15,447
Non-controlling interests	(86)	31
Net profit for the period	**13,854**	**15,478**
Total comprehensive income attributable to		
Owners of the company	22,188	13,973
Non-controlling interests	(99)	19
Total comprehensive income	**22,089**	**13,992**
Earnings per share		
Basic earnings per share (yen)	41.76	48.05
Diluted earnings per share (yen)	41.70	47.97

Core basis (JPY millions)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Core operating profit	22,314	23,932

(2) Condensed Interim Consolidated Statements of Financial Position

Assets (JPY millions)

	As of March 31, 2026	As of September 30, 2026
Non-current assets		
Property, plant and equipment	78,115	82,377
Intangible assets	71,658	69,569
Financial assets	19,940	19,941
Retirement benefit assets	11,379	11,265
Deferred tax assets	10,843	9,812
Other non-current assets	2,339	2,804
Total non-current assets	**194,274**	**195,768**
Current assets		
Inventories	64,584	65,439
Trade and other receivables	71,754	62,906
Other financial assets	2,475	1,095
Income taxes receivable	76	35
Other current assets	8,994	9,585
Cash and cash equivalents	80,875	81,657
Subtotal	**228,758**	**220,717**
Assets of disposal groups classified as held for sale	—	1,965
Total current assets	**228,758**	**222,682**
Total assets	**423,033**	**418,450**

Equity and liabilities (JPY millions)

	As of March 31, 2026	As of September 30, 2026
Equity		
Equity attributable to owners of the company		
Share capital	8,824	8,846
Capital surplus	9,595	8,952
Treasury shares	(979)	(878)
Retained earnings	223,285	232,735
Other components of equity	56,263	54,446
Other components of equity of disposal groups classified as held for sale	—	184
Total equity attributable to owners of the company	**296,989**	**304,284**
Non-controlling interests	**(972)**	**(953)**
Total equity	**296,017**	**303,331**
Liabilities		
Non-current liabilities		
Financial liabilities	31,219	32,156
Net defined benefit liabilities	1,424	1,228
Income taxes payable	31	—
Provisions	731	715
Deferred tax liabilities	4,338	3,788
Other non-current liabilities	1,405	2,009
Total non-current liabilities	**39,147**	**39,897**
Current liabilities		
Trade and other payables	35,350	31,692
Other financial liabilities	27,529	25,771
Income taxes payable	4,535	3,917
Provisions	1,404	1,097
Other current liabilities	19,050	12,507
Subtotal	**87,868**	**74,985**
Liabilities of disposal groups classified as held for sale	—	237
Total current liabilities	**87,868**	**75,222**
Total liabilities	**127,015**	**115,120**
Total equity and liabilities	**423,033**	**418,450**

(3) Condensed Interim Consolidated Statements of Changes in Equity

Six months ended September 30, 2025 (JPY millions)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		
					Remeasurements of defined benefit plans	Net gain or loss on financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations
Balance at April 1, 2025	8,806	9,797	(1,161)	228,291	—	2,616	37,629
Comprehensive income							
Net profit for the period				13,940			
Other comprehensive income						380	7,868
Total comprehensive income	—	—	—	13,940	—	380	7,868
Transactions with owners							
Issuance of new shares	11	11					
Repurchase of treasury shares		(19)	(27,774)				
Disposal of treasury shares			925				
Dividends				(6,487)			
Share-based payments		(309)					
Total transactions with owners	11	(317)	(26,849)	(6,487)	—	—	—
Balance at September 30, 2025	8,816	9,480	(28,009)	235,744	—	2,996	45,497

(JPY millions)

	Other components of equity			Other components of equity of disposal groups classified as held for sale	Total equity attributable to owners of the company	Non-controlling interests	Total equity
	Share of other comprehensive income of investments accounted for using equity method	Share acquisition rights	Total				
Balance at April 1, 2025	140	124	40,509	—	286,242	(1,061)	285,181
Comprehensive income							
Net profit for the period			—		13,940	(86)	13,854
Other comprehensive income			8,248		8,248	(13)	8,235
Total comprehensive income	—	—	8,248	—	22,188	(99)	22,089
Transactions with owners							
Issuance of new shares		(21)	(21)		0		0
Repurchase of treasury shares			—		(27,793)		(27,793)
Disposal of treasury shares			—		925		925
Dividends			—		(6,487)		(6,487)
Share-based payments			—		(309)		(309)
Total transactions with owners	—	(21)	(21)	—	(33,663)	—	(33,663)
Balance at September 30, 2025	140	103	48,736	—	274,767	(1,160)	273,607

Six months ended September 30, 2026 (JPY millions)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		
					Remeasurements of defined benefit plans	Net gain or loss on financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations
Balance at April 1, 2026	8,824	9,595	(979)	223,285	—	4,780	51,255
Comprehensive income							
Net profit for the period				15,447			
Other comprehensive income						(84)	(1,250)
Total comprehensive income	—	—	—	15,447	—	(84)	(1,250)
Transactions with owners							
Issuance of new shares	22	22					
Repurchase of treasury shares			(955)				
Disposal of treasury shares		17	1,056				
Dividends				(6,112)			
Share-based payments		(683)					
Transfer to other components of equity of disposal groups classified as held for sale							(184)
Other				115		(115)	
Total transactions with owners	22	(644)	101	(5,998)	—	(115)	(184)
Balance at September 30, 2026	8,846	8,952	(878)	232,735	—	4,581	49,822

(JPY millions)

	Other components of equity			Other components of equity of disposal groups classified as held for sale	Total equity attributable to owners of the company	Non-controlling interests	Total equity
	Share of other comprehensive income of investments accounted for using equity method	Share acquisition rights	Total				
Balance at April 1, 2026	140	88	56,263	—	296,989	(972)	296,017
Comprehensive income							
Net profit for the period			—		15,447	31	15,478
Other comprehensive income	(140)		(1,474)		(1,474)	(12)	(1,486)
Total comprehensive income	(140)	—	(1,474)	—	13,973	19	13,992
Transactions with owners							
Issuance of new shares		(45)	(45)		0		0
Repurchase of treasury shares			—		(955)		(955)
Disposal of treasury shares			—		1,072		1,072
Dividends			—		(6,112)		(6,112)
Share-based payments			—		(683)		(683)
Transfer to other components of equity of disposal groups classified as held for sale			(184)	184	—		—
Other			(115)		—		—
Total transactions with owners	—	(45)	(343)	184	(6,678)	—	(6,678)
Balance at September 30, 2026	—	43	54,446	184	304,284	(953)	303,331

(4) Condensed Interim Consolidated Statements of Cash Flows

(JPY millions)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Ⅰ. Cash flows from operating activities:		
Net profit for the period	13,854	15,478
Depreciation and amortization	9,188	8,949
Interest income, dividend income and interest expenses (increase)	(81)	(181)
Income tax expenses	3,780	4,381
Decrease (increase) in trade and other receivables	10,178	8,301
Decrease (increase) in inventories	(6,121)	(1,561)
Increase (decrease) in trade and other payables	(8,682)	(3,633)
Increase (decrease) in provisions and net defined benefit liabilities	(599)	(342)
Decrease (increase) in other current assets	(135)	(396)
Increase (decrease) in accounts payable - bonuses	(2,170)	(3,191)
Increase (decrease) in accounts payable - other	(2,947)	(2,278)
Increase (decrease) in deposits received	(638)	(1,734)
Other	924	617
Subtotal	16,551	24,410
Interest received	404	443
Dividends received	176	176
Interest paid	(574)	(800)
Income tax paid	(2,984)	(4,520)
Net cash flows from (used in) operating activities	**13,573**	**19,710**
Ⅱ. Cash flows from investing activities:		
Payments for acquisition of investment securities	(103)	―
Proceeds from sale of investment securities	―	115
Payments for acquisition of property, plant and equipment	(3,388)	(4,876)
Payments for acquisition of intangible assets	(6,049)	(3,933)
Other	(32)	39
Net cash flows from (used in) investing activities	**(9,572)**	**(8,655)**
Ⅲ. Cash flows from financing activities:		
Purchase of treasury shares	(27,793)	(955)
Dividends paid	(6,479)	(6,110)
Repayments of lease obligation	(1,695)	(1,715)
Other	2	0
Net cash flows from (used in) financing activities	**(35,964)**	**(8,780)**
Ⅳ. Net increase (decrease) in cash and cash equivalents	**(31,963)**	**2,275**
Ⅴ. Cash and cash equivalents at the beginning of period	**92,997**	**80,875**
Ⅵ. Effect of exchange rate changes on cash and cash equivalents	**2,526**	**(803)**
Ⅶ. Cash and cash equivalents included in assets of disposal groups classified as held for sale	**―**	**(690)**
Ⅷ. Cash and cash equivalents at the end of period	**63,560**	**81,657**

(5) Notes to Condensed Interim Consolidated Financial Statements

(Going Concern Assumption)

Not applicable.

(Segment Information and Others)

Segment information is omitted because the Santen Group is a single segment.

(Statement of Significant Changes in Shareholders' Equity)

Six months ended September 30, 2025

(Repurchase of own shares)

At a meeting of the Board of Directors on May 13, 2025, the Board resolved to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3. Santen repurchased a total of 16,575,400 of its own shares for a total value of 26,897 million yen during the period between May 22, 2025 to September 30, 2025.

(I) Reasons for repurchase of own shares

Santen considers returning profits to shareholders as one of its top management priorities. Taking into consideration its business environment and financial condition, Santen decided to implement a share buyback to enhance shareholder returns and capital efficiency.

(II) Details of repurchase

(1) Class of shares to be acquired	Common shares
(2) Total number of shares to be acquired	19,800,000 shares (maximum) *Representing 5.8% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of acquisition	35.0 billion yen (maximum)
(4) Period of acquisition	May 22, 2025 to November 5, 2025
(5) Method of acquisition	Open-market repurchase by discretionary trading method

Six months ended September 30, 2026

There were no significant transactions.

(Disposal groups classified as held for sale)

At a meeting of the Board of Directors on September 10, 2026, the Board resolved to transfer all outstanding shares of its wholly owned U.S. subsidiary, Advanced Vision Science, Inc. (hereinafter “AVS”), to SpyGlass Pharma, Inc. in the U.S.. Accordingly, the assets and liabilities of AVS have been classified as a disposal group classified as held for sale during the six months ended September 30, 2026.

As described in “Significant Subsequent Events,” the transfer of all outstanding shares of AVS was completed on October 1, 2026.

Disposal groups classified as held for sale consist of the following items:

(JPY millions)

	Year ended March 31, 2026	Six months ended September 30, 2026
Assets of disposal groups classified as held for sale		
Property, plant and equipment	—	233
Intangible assets	—	10
Financial assets	—	2
Inventories	—	710
Trade and other receivables	—	270
Other current assets	—	49
Cash and cash equivalents	—	690
Total assets	—	1,965
Liabilities of disposal groups classified as held for sale		
Financial liabilities	—	26
Other non-current liabilities	—	7
Trade and other payables	—	1
Other financial liabilities	—	121
Provisions (current)	—	56
Other current liabilities	—	27
Total liabilities	—	237

Other components of equity of disposal groups classified as held for sale amounted to ¥184 million.

(Significant Subsequent Events)

(I) Transfer of shares of a subsidiary

On October 1, 2026, the Santen Group transferred all outstanding shares of its U.S. subsidiary, Advanced Vision Science, Inc. (hereinafter “AVS”), to SpyGlass Pharma, Inc. in the U.S.. As a result, AVS was excluded from the Santen Group’s consolidated subsidiaries. In connection with the share transfer, a gain on the sale of shares of a subsidiary of around ¥0.8 billion is expected to be recognized in “Other income” for the year ending March 31, 2027. In the condensed interim consolidated statements of financial position for the six months ended September 30, 2026, the assets and liabilities of AVS have been classified as held for sale. For related information, please refer to “Disposal Groups Classified as Held for Sale.”

(II) Resolution on Repurchase of Own Shares (Acquisition of Own Shares Pursuant to Provisions in the Articles of Incorporation Under Article 165, Paragraph 2 of the Companies Act)

At a meeting of the Board of Directors on November 5, 2026, the Board resolved to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

(1) Reasons for repurchase of own shares

Santen considers returning profits to shareholders as one of its top management priorities. Taking into consideration its business environment and financial conditions, Santen decided to implement a share buyback to enhance shareholder returns, further improve capital efficiency and pursue a flexible capital policy.

(2) Details of repurchase

(1) Class of shares to be acquired	Common shares
(2) Total number of shares to be acquired	16,000,000 shares (maximum) *Representing 5.0% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of acquisition	35.0 billion yen (maximum)
(4) Period of acquisition	November 6, 2026 to May 10, 2027
(5) Method of acquisition	Open-market repurchase by discretionary trading method
(6) Other	Santen plans to cancel the repurchased shares as resolved by the Board of Directors in accordance with Article 178 of the Companies Act (Japan). There is a possibility that some of the purchases may not be made depending on market conditions and other factors.

3. Consolidated Reference
(1) Revenue of Major Products

(JPY billions)

Brand Name	Region	Year ended March 31, 2026		Year ending March 31, 2027			
		Six months ended September 30, 2025 Actual	Year ended March 31, 2026 Actual	Six months ended September 30, 2026 Actual	Changes from the same period of previous year	Forecast for the fiscal year ending March 31, 2027	Changes from the same period of previous year
Glaucoma and ocular hypertension							
Cosopt	Total	13.2	28.2	15.4	16.7%	27.9	(0.9%)
	Japan	0.9	1.7	0.7	(24.5%)	1.2	(26.2%)
	Asia	3.4	7.2	3.9	14.7%	7.6	5.4%
	EMEA	8.9	19.2	10.8	21.7%	19.0	(1.0%)
Tapros	Total	7.9	15.9	8.1	2.1%	15.4	(3.5%)
	Japan	1.2	2.3	0.8	(33.5%)	1.6	(30.3%)
	China	1.2	2.6	1.5	23.4%	2.6	0.2%
	Asia	1.2	2.4	1.3	2.7%	2.5	1.8%
	EMEA	4.3	8.6	4.5	6.2%	8.7	1.0%
Tapcom	Total	4.7	9.4	4.7	(0.3%)	9.5	0.9%
	Japan	0.6	1.1	0.4	(27.5%)	0.7	(31.9%)
	China	0.0	0.1	0.1	92.0%	0.3	208.9%
	Asia	0.8	1.6	0.9	6.9%	2.0	22.2%
	EMEA	3.3	6.7	3.4	1.9%	6.5	(2.1%)
Eybelis	Total	2.8	5.7	3.1	9.6%	5.8	2.6%
	Japan	2.4	4.7	2.4	2.6%	4.5	(4.2%)
	Asia	0.4	0.9	0.6	47.9%	1.3	37.8%
Catiolanze	Total	0.3	1.0	0.8	142.8%	2.6	176.0%
	EMEA	0.3	1.0	0.8	142.8%	2.6	176.0%
Rhopressa/Rhokiinsa	Total	0.1	0.2	0.4	274.7%	1.3	597.7%
	Japan	–	–	0.2	–	1.0	–
	Asia	0.1	0.2	0.1	9.9%	0.3	67.4%
	EMEA	0.0	0.0	0.0	71.2%	0.0	14.5%
Rocklatan/Roclanda	Total	0.6	1.5	0.9	36.6%	2.4	65.2%
	Asia	0.0	0.0	0.0	103.7%	0.0	12.3%
	EMEA	0.6	1.5	0.9	35.5%	2.4	66.2%
Setaneo	Total	–	0.5	0.6	–	1.6	260.9%
	Japan	–	0.5	0.6	–	1.6	260.9%
Alphagan/AlphaganP	Total	–	–	0.5	–	2.5	–
	China	–	–	0.5	–	2.5	–
Dry eye							
Diquas	Total	5.4	10.2	4.1	(25.2%)	9.1	(10.9%)
	Japan	3.5	6.1	2.3	(34.8%)	4.2	(30.4%)
	China	0.9	1.8	0.6	(33.6%)	2.3	27.5%
	Asia	1.1	2.3	1.2	11.3%	2.6	9.8%
Diquas LX	Total	–	1.9	2.6	–	6.9	268.4%
	Japan	–	1.9	2.6	–	6.9	268.4%
Hyalein	Total	8.1	16.2	7.7	(4.7%)	17.0	5.1%
	Japan	1.9	3.5	1.4	(23.4%)	2.8	(21.5%)
	China	4.2	8.2	3.6	(13.3%)	9.3	13.5%
	Asia	2.0	4.5	2.6	31.7%	4.9	10.7%
Ikervis	Total	6.1	13.6	7.7	25.4%	15.2	11.2%
	Asia	1.0	2.2	1.3	22.2%	2.6	17.0%
	EMEA	5.1	11.4	6.4	24.8%	12.4	9.1%
Cationorm	Total	1.9	3.4	2.4	24.2%	4.5	29.5%
	China	0.1	0.2	0.2	38.5%	0.2	44.3%
	Asia	0.4	0.8	0.6	49.2%	1.0	22.9%
	EMEA	1.3	2.4	1.7	22.5%	3.2	34.9%
Allergy							
Alesion *1	Total	6.4	26.8	5.4	(15.9%)	24.2	(10.0%)
	Japan	6.2	26.4	5.1	(17.6%)	23.4	(11.2%)
	Asia	0.2	0.4	0.3	31.2%	0.7	65.7%
Verkazia	Total	1.3	2.4	1.9	41.1%	3.7	55.8%
	China	0.0	0.1	0.2	–	0.5	792.9%
	EMEA	1.3	2.3	1.7	30.1%	3.3	39.7%
Intravitreal VEGF inhibitor							
EYLEA *2	Total	36.4	65.6	26.7	(26.8%)	56.1	(14.5%)
	Japan	36.4	65.6	26.7	(26.8%)	56.1	(14.5%)
Beovu	Total	–	1.4	1.9	–	4.1	184.5%
	Asia	–	1.4	1.9	–	4.1	184.5%
Bacterial conjunctivitis							
Cravit	Total	6.6	13.8	8.0	21.4%	14.9	7.8%
	Japan	0.2	0.4	0.2	(34.3%)	0.3	(23.8%)
	China	4.2	8.9	5.3	26.5%	9.6	7.7%
	Asia	1.4	3.0	1.6	15.2%	3.4	14.4%
	EMEA	0.7	1.5	0.9	23.4%	1.6	4.5%
Slowing myopia progression							
Ryjusea/Ryjunea	Total	0.6	1.6	1.8	219.0%	6.0	273.4%
	Japan	0.4	1.1	1.3	194.0%	4.0	264.5%
	EMEA	0.1	0.5	0.6	293.5%	2.0	291.4%
Ptosis							
Upneeq	Total	–	–	0.4	–	1.4	–
	Japan	–	–	0.4	–	1.4	–
Medical devices							
PRESERFLO MicroShunt	Total	3.7	8.1	4.6	22.3%	9.7	19.5%
	Japan	1.1	2.4	1.3	17.6%	2.8	16.1%
	Asia	0.1	0.2	0.1	8.4%	0.3	48.3%
	EMEA	2.5	5.6	3.1	24.4%	6.7	20.1%
OTC Pharmaceuticals	Total	6.4	12.2	6.5	1.5%	12.5	2.9%
	Japan	6.0	11.4	6.1	0.7%	11.7	2.8%
	Asia	0.4	0.8	0.4	14.7%	0.8	4.8%

Forecasts in this report are based on the currently available information. Actual results may differ materially depending on a number of factors including changes to the business environment and others. Our full-year forecasts are based on our foreign exchange assumptions. Revenue by region shows that of major countries or regions.

*1 Including *Alesion* LX, *Alesion* eyelid cream, *Epinastine* hydrochloride and *Epinastine* hydrochloride LX

*2 Co-promoted product of Bayer Yakuhin, Ltd. (MAH); including *EYLEA* 8mg, *EYLEA* 8mg intraocular injection kit, and Aflibercept intraocular injection kit "*Bayer*" of Bayer Life Science, Ltd. (MAH).

(2) Research & Development

As of October 2026

Pipeline Development Status (Clinical Stage)

<Glaucoma and ocular hypertension area>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
omidenepag isopropyl	STN1011702	Glaucoma/ Ocular hypertension	Co-development with UBE Corporation	China						
A unit dose, preservative-free eye drop, EP2 receptor agonist with a new mechanism of action, sold in Japan and Asia. Completed Phase 3 in China in September 2026, having met its primary endpoint.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
latanoprost	STN1013001 / DE-130A (Catioprost)	Glaucoma / Ocular hypertension	Original	Europe						Aug-2024
				Asia				Nov-2024		
An ophthalmic emulsion of a prostaglandin $F_{2\alpha}$ derivative, for the treatment of glaucoma and ocular hypertension. Filed for marketing approval in Asia in November 2024. Launched in European countries including Spain in August 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate	STN1013900 / AR-13324	Glaucoma / Ocular hypertension	Alcon Inc.	Japan						Aug-2026
				Europe						Feb-2023
				Asia						Nov-2024
ROCK (Rho-associated kinase)/NET (norepinephrine transporter) inhibitor. Developed and sold by Alcon Inc. in the U.S.. Launched in Japan in August 2026. Received marketing approval in Europe and has been launched in Sweden and other countries from February 2023. Successively received marketing approval in Asian countries and launched in South Korea in November 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate / latanoprost	STN1014003	Glaucoma / Ocular hypertension	Alcon Inc.	Japan						
A fixed dose combination drug of a ROCK (Rho-associated kinase)/NET (norepinephrine transporter) inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Developed and sold by Alcon Inc. in the U.S.. Met its primary endpoint in the pivotal phase of Phase 3 being conducted in Japan from February 2025.										

<Keratoconjunctival disease area including dry eye >

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
diquafosol sodium	STN1008903 / DE-089C	Dry eye	Merck Sharp & Dohme Corp. (U.S.)	Asia				May-2026		
A dry eye treatment which stimulates secretion of mucin and aqueous components from the corneal and conjunctival epithelium. Long-acting drug. Launched in November 2022 in Japan. Filed for marketing approval in Asia in May 2026.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
olodaterol hydrochloride	STN1014100	Dry eye	Boehringer Ingelheim	Japan	(Phase 2b)					
β_2 receptor agonist. Completed Phase 2b in Japan in August 2026, having met its primary endpoint.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
olodaterol hydrochloride	STN1014101	Allergic conjunctivitis	Boehringer Ingelheim	Japan	(Phase 1/2a)					
β_2 receptor agonist. Started Phase 1/2a in Japan in March 2026.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
epinastine hydrochloride	STN1011402	Allergic conjunctivitis	Nippon Boehringer Ingelheim	Japan						May-2024
				China						
A histamine H_1 receptor antagonist with mediator release inhibitor function, as a treatment for allergic conjunctivitis. Ophthalmic eyelid cream. Launched in Japan in May 2024. Started Phase 3 in China in January 2026.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
epinastine hydrochloride	STN1011403	Allergic conjunctivitis	Boehringer Ingelheim	China				Mar-2025		
A histamine H_1 receptor antagonist with mediator release inhibitor function, as a treatment for allergic conjunctivitis. High dose formulation to instill twice a day. Filed for marketing approval in China in March 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
nintedanib	STN1014200 / CBT-001	Pterygium	Cloudbreak Pharma Inc.	Japan	(Phase 2b)					
A multi-kinase inhibitor which suppresses angiogenesis and fibrosis. Conducting Phase 2b in Japan from November 2025.										

< Refractive disorder>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
atropine sulfate	STN1012700 / DE-127	Myopia	Singapore Health Services, Nanyang Technological University	Japan						Apr-2025
				China					Sep-2026	
				Asia					May-2026	
Non-selective muscarinic antagonist which reduces the progression of juvenile myopia. Launched in Japan in April 2025. Filed for marketing approval in China in September 2026. In Asia, received marketing approval in the Philippines in May 2026.										

< Retinal diseases area >

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
eflimrufusp alfa	STN1014300 / RC28-E	Diabetic macular edema	RemeGen Co., Ltd.	China						
Dual decoy receptor IgG1 Fc-fusion protein drug simultaneously blocks both VEGF-A and FGF-2. RemeGen Co., Ltd., the licensor, withdrew filing for marketing approval in China in June 2026 and plans additional trials to fulfill final approval requirements.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
eflimrufusp alfa	STN1014301 / RC28-E	Wet age-related macular degeneration	RemeGen Co., Ltd.	China						
Dual decoy receptor IgG1 Fc-fusion protein drug simultaneously blocks both VEGF-A and FGF-2. RemeGen Co., Ltd., the licensor, completed Phase 3 trial in China in April 2026, having met its primary endpoint.										

<Others>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
oxymetazoline hydrochloride	STN1013800	Ptosis	RVL Pharmaceuticals	Japan						May-2026
				Europe						
				China						
				Asia					Aug-2026	
A direct-acting alpha adrenergic receptor agonist. Developed and sold by RVL Pharmaceuticals in the U.S.. Launched in Japan in May 2026. Conducting Phase 3 in Europe from December 2024. Conducting Phase 3 in China from October 2024. Filed for marketing approval in Asia in August 2026.										

Changes from Q1 FY2026 (August 6, 2026)

Dev. Code	Changes
STN1011702	Completed Phase 3 in China in September 2026, having met its primary endpoint.
STN1013900 / AR-13324	Launched in Japan in August 2026.
STN1014100	Completed Phase 2b in Japan in August 2026, having met its primary endpoint.
STN1012700 / DE-127	Filed for marketing approval in China in September 2026.
STN1013800	Filed for marketing approval in Asia in August 2026.

(3) Capital Expenditures, Depreciation and Amortization, Amortization of Intangible Assets Associated with Products, and Research and Development Expenses

Capital expenditures (JPY billions)

	Six months ended September 30, 2025	Year ended March 31, 2026	Six months ended September 30, 2026	Year ending March 31, 2027
	Actual			Forecast
Consolidated	3.9	7.3	5.9	22.5

(Note):
Excluding the increase in right-of-use assets.

Depreciation and amortization (JPY billions)

	Six months ended September 30, 2025	Year ended March 31, 2026	Six months ended September 30, 2026	Year ending March 31, 2027
	Actual			Forecast
Manufacturing cost	1.9	3.9	2.0	4.2
Selling, general and administrative expenses	1.3	2.5	1.1	2.6
R&D expenses	0.3	0.6	0.4	0.6
Consolidated total	3.5	7.0	3.5	7.3

(Note):
Excluding amortization on intangible assets associated with products, long-term advance expense and right-of-use assets.

Amortization on intangible assets associated with products (JPY billions)

	Six months ended September 30, 2025	Year ended March 31, 2026	Six months ended September 30, 2026	Year ending March 31, 2027
	Actual			Forecast
Intangible assets (Merck products)	2.2	4.4	1.6	2.2
Intangible assets (*Rhopressa/Rocklatan*)	0.9	1.9	1.0	2.0
Intangible assets (*PRESERFLO MicroShunt*)	0.6	1.3	0.7	1.3
Intangible assets (*Upneeq*)	—	—	0.4	0.9
Intangible assets (*Ikervis*)	0.5	0.6	—	—
Other	0.2	0.6	0.4	1.3
Consolidated total	4.4	8.8	4.1	7.7

Research and development expenses (JPY billions)

	Six months ended September 30, 2025	Year ended March 31, 2026	Six months ended September 30, 2026	Year ending March 31, 2027
	Actual			Forecast
Core basis	12.4	25.6	12.1	27.5

(4) FOREX

(JPY)

Major currency	Six months ended September 30, 2025	Fiscal year ended March 31, 2026	Six months ended September 30, 2026	Fiscal year ending March 31, 2027 (Forecasts)
USD	146.23	150.79	159.50	155.00
EUR	167.79	174.71	184.35	180.00
CNY	20.39	21.29	23.47	23.00

*Forecasts in this report are based on currently available information. Actual results may differ materially depending on a number of factors including changes to the business environment and others.